Cargando…

Immunotherapy in other thoracic malignancies and uncommon populations

Detalles Bibliográficos
Autores principales:	Remon, Jordi, Besse, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Editorial on Immunotherapy in Other Thoracic Malignancies and Uncommon Populations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264332/ https://www.ncbi.nlm.nih.gov/pubmed/34295684 http://dx.doi.org/10.21037/tlcr-21-456

Ejemplares similares

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
por: Ferrara, Roberto, et al.
Publicado: (2021)

Narrative review of immunotherapy in thymic malignancies
por: Benitez, Jose Carlos, et al.
Publicado: (2021)

Immunotherapy in malignant pleural mesothelioma: a review of literature data
por: Menis, Jessica, et al.
Publicado: (2021)

Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
por: Duchemann, Boris, et al.
Publicado: (2021)

Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
por: Hendriks, Lizza E. L., et al.
Publicado: (2021)

Immunotherapy in small cell lung cancer: one step at a time: a narrative review
por: Dumoulin, Daphne W., et al.
Publicado: (2021)

Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review
por: Naltet, Charles, et al.
Publicado: (2021)

First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease
por: Passiglia, Francesco, et al.
Publicado: (2021)

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
por: Guaitoli, Giorgia, et al.
Publicado: (2021)

Radiotherapy in thoracic malignancies: the preface
por: Jassem, Jacek, et al.
Publicado: (2021)

Healthcare disparities in thoracic malignancies
por: Suzuki, Kei, et al.
Publicado: (2021)

The efficacy of immune checkpoint inhibitors in thoracic malignancies
por: Remon, Jordi, et al.
Publicado: (2021)

Uncommon of the Uncommon: Malignant Perivascular Epithelioid Cell Tumor of the Lung
por: Lim, Hyun-ju, et al.
Publicado: (2013)

Epitope-based precision immunotherapy of Type 1 diabetes
por: Firdessa Fite, Rebuma, et al.
Publicado: (2023)

The relationship between sublingual immunotherapy for allergic rhinitis and the risk of symptoms in patients with COVID-19 infection
por: Zhang, Shipeng, et al.
Publicado: (2023)

Progress in Guillain–Barré syndrome immunotherapy—A narrative review of new strategies in recent years
por: Yao, Jiajia, et al.
Publicado: (2023)

IL-7 producing immunotherapy improves ex vivo T cell functions of immunosenescent patients, especially post hip fracture
por: Marton, Chrystel, et al.
Publicado: (2023)

Current status, challenges and perspectives: immunotherapy and tumour microenvironment in thoracic cancer
por: Luo, Peng, et al.
Publicado: (2020)

Thoracic radiotherapy in small cell lung cancer—a narrative review
por: Levy, Antonin, et al.
Publicado: (2021)

Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies
por: Ekeke, Chigozirim N., et al.
Publicado: (2021)

Reporting of patient safety incidents in minimally invasive thoracic surgery: a national registered thoracic surgeons experience for improvement of patient safety
por: Bottet, Benjamin, et al.
Publicado: (2022)

The population bomb /
por: Ehrlich, Paul R.
Publicado: (1995)

IMMU-02. Targeted innovative antibody fragment-based immunotherapy for medulloblastoma
por: Niesen, Judith, et al.
Publicado: (2022)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy
por: Vanneste, Ben G. L., et al.
Publicado: (2021)

IMMU-15. PROTEOGENOMIC DISCOVERY OF NOVEL TUMOR PEPTIDES AS NEOANTIGENS FOR PERSONALIZED T CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA
por: Rivero-Hinojosa, Samuel, et al.
Publicado: (2020)

The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research
por: Smith, Alexandra, et al.
Publicado: (2010)

Immunotherapy in Thoracic Malignancies: New Treatment and New Hope
por: Melosky, Barbara
Publicado: (2022)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

IMMU-16. INTRA-TUMOURAL IL-12 DELIVERY ENABLES CAR T-CELL IMMUNOTHERAPY FOR HIGH-GRADE GLIOMA
por: Agliardi, Giulia, et al.
Publicado: (2020)

Women in Thoracic Surgery in Africa: a call for intersocietal coalition
por: Pompili, Cecilia, et al.
Publicado: (2022)

Long-Term Risk of Subsequent Malignant Neoplasms Among Childhood and Adolescent Lymphoma Survivors (1975-2013): A Population-Based Predictive Nomogram
por: Liu, Junqi, et al.
Publicado: (2023)

Extended, virtual and augmented reality in thoracic surgery: a systematic review
por: Arjomandi Rad, Arian, et al.
Publicado: (2021)

Feasibility and long-term outcomes of surgery for primary thoracic synovial sarcoma
por: Pieropan, Sara, et al.
Publicado: (2022)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial
por: Bröckelmann, Paul J., et al.
Publicado: (2022)

Preclinical evaluation of Versius, an innovative device for use in robot-assisted thoracic surgery
por: Aresu, Giuseppe, et al.
Publicado: (2022)

IMMU-12. PHASE I/II TRIAL OF IMMUNOTHERAPY WITH FUSIONS OF DENDRITIC CELLS AND TUMOR CELLS FOR RELAPSED OR REFRACTORY BRAIN TUMORS IN CHILDREN AND YOUNG ADULTS
por: Yamaoka, Masayoshi, et al.
Publicado: (2020)

Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer
por: Sprooten, Jenny, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_adt1bh4umnum86hq917do63lvd